Cardurion Announces Late-Breaking Phase 2 Tovinontrine Results in Heart Failure
Burlington, Mass. – August 27, 2026 Cardurion Pharmaceuticals announced that it will present late-breaking results from two Phase 2...
Bone Health
Advertisement
MBX Biosciences Doses First Patient in Phase 3 oPTimize Trial of Canvuparatide
Carmel, Indiana and Burlington, Massachusetts – August 27, 2026 MBX Biosciences announced that the first patient has been dosed...
Accord BioPharma Launches Two Denosumab Biosimilars
RALEIGH, N.C., July 23, 2026 Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has announced the commercial...
DarioHealth and Beluga Partner to Transform Digital Chronic Care
NEW YORK, June 29, 2026 DarioHealth Corp. has announced a strategic collaboration with Beluga Health to create a provider-backed,...
Talawar Therapeutics to Go Public in JATT II Merger
NEW YORK & WESTFIELD, N.J., June 29, 2026 Talawar Therapeutics has announced a definitive business combination agreement with JATT...
Advertisements
Organon Launches BILDYOS® and TUZEMTY® in Canada
KIRKLAND, Quebec, Canada & SHANGHAI, China, June 23, 2026 Organon Canada and Shanghai Henlius Biotech have expanded access to...
Nabsys and LUMC Advance FSHD Research With Genome Mapping
PROVIDENCE, R.I., June 15, 2026 Nabsys 2.0, LLC has announced a strategic research collaboration with Leiden University Medical Center...
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
AstraZeneca Reports Positive Phase III Results for Eneboparatide in HypoPT
PRAGUE, Czech Republic, May 12, 2026 AstraZeneca and Alexion announced positive Phase III clinical trial results for eneboparatide (AZP-3601),...
Apotex Wins Approval for DENOZA Biosimilar in Canada
TORONTO, Ontario, Canada, April 7, 2026 Apotex Inc., a leading global pharmaceutical company, announced that Health Canada has approved...
Advertisement
